Latest Period
Q1 2026
Security Snapshot
Indivior Pharmaceuticals, Inc. - Common stock, $0.001 par value per share (the "Common Stock") (INDV) Institutional Ownership
CUSIP: G4766E116
13F Institutional Holders and Ownership History from Q2 2023 to Q1 2026
Institutions Reporting
3
Shares (Excl. Options)
214,389
Price
$30.48
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common stock, $0.001 par value per share (the "Common Stock")
- Symbol
- INDV on Nasdaq
- Shares outstanding
- 123,290,343
- Price per share
- $30.48
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 214,389
- Total reported value
- $6,535,613
- % of total 13F portfolios
- 0%
- Share change
- -107,323,760
- Value change
- -$3,849,183,944
- Number of holders
- 3
- Price from insider filings
- $30.48
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- INDV - Indivior Pharmaceuticals, Inc. - Common stock, $0.001 par value per share (the "Common Stock") is tracked under CUSIP G4766E116.
- 3 institutions reported positions in Q1 2026.
- 11 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 246 to 3 between Q4 2025 and Q1 2026.
- Reported value moved from $4,053,440,060 to $6,535,613.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 3 institutions filings for Q1 2026.
Security key
G4766E116
Latest holder period
Q1 2026
13F holders
3
13D/G owners
11
CIK / CUSIP context first
Open Q1 2026 holders
INDV full holder history
Indivior Pharmaceuticals, Inc. SEC filings
Indivior Pharmaceuticals, Inc. company facts
Indivior Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G4766E116:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
11
Security
INDV
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 14% | +107% | $638,884,065 | +$335,082,637 | 17,806,183 | +110% | BlackRock, Inc. | 31 Dec 2025 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.6% | $272,463,211 | 7,994,836 | Vanguard Portfolio Management | 31 Mar 2026 | |||
| Oaktree Capital Holdings, LLC | 5.7% | -19% | $232,808,746 | -$53,592,755 | 7,108,664 | -19% | Oaktree Capital Holdings, LLC | 24 Dec 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.4% | $222,327,725 | 6,523,720 | Vanguard Capital Management | 31 Mar 2026 | |||
| Two Seas Capital LP | 5% | -12% | $203,438,218 | -$27,837,500 | 6,211,854 | -12% | Two Seas Capital LP | 23 Dec 2025 |
| MILLENNIUM MANAGEMENT LLC | 3.8% | +90% | $158,472,151 | +$77,320,782 | 4,806,556 | +95% | Millennium Management LLC | 17 Mar 2026 |
| MORGAN STANLEY | 3.7% | $53,976,433 | 4,665,206 | Morgan Stanley | 31 Mar 2025 | |||
| Flynn James E | 3.7% | -60% | $111,255,547 | -$143,518,681 | 4,614,498 | -56% | Deerfield Mgmt, L.P. | 10 Nov 2025 |
| FULLER & THALER ASSET MANAGEMENT, INC. | 3.7% | -28% | $146,214,501 | -$59,457,962 | 4,529,583 | -29% | Fuller & Thaler Asset Management, Inc. | 31 Mar 2026 |
| Madison Avenue Partners, LP | 3.5% | -30% | $139,292,998 | -$63,440,979 | 4,315,162 | -31% | Madison Avenue International LP | 31 Mar 2026 |
| GOLDMAN SACHS GROUP INC | 2.9% | -46% | $122,142,647 | -$99,940,892 | 3,592,431 | -45% | THE GOLDMAN SACHS GROUP, INC. | 31 Dec 2025 |
As of 31 Mar 2026, 3 institutional investors reported holding 214,389 shares of Indivior Pharmaceuticals, Inc. - Common stock, $0.001 par value per share (the "Common Stock") (INDV). This represents 0.17% of the company’s total 123,290,343 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
12
Latest
Q1 2026
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 214,389 | $6,535,613 | -$3,849,183,944 | $30.48 | 3 |
| 2025 Q4 | 113,035,456 | $4,053,440,060 | -$18,859,469 | $35.88 | 246 |
| 2025 Q3 | 110,811,392 | $2,670,071,230 | +$380,369,121 | $24.11 | 196 |
| 2025 Q2 | 106,959,206 | $1,577,697,144 | +$260,685,760 | $14.74 | 119 |
| 2025 Q1 | 91,341,313 | $865,955,709 | +$119,981,356 | $9.53 | 115 |
| 2024 Q4 | 77,790,536 | $974,764,447 | +$68,457,241 | $12.43 | 112 |
| 2024 Q3 | 71,540,427 | $699,253,141 | +$54,237,351 | $9.75 | 100 |
| 2024 Q2 | 64,306,768 | $1,024,584,616 | -$11,033,099 | $16.12 | 95 |
| 2024 Q1 | 63,276,125 | $1,352,112,050 | +$24,497,831 | $21.42 | 86 |
| 2023 Q4 | 63,746,436 | $970,147,653 | -$75,831,576 | $15.27 | 69 |
| 2023 Q3 | 67,913,856 | $1,531,662,383 | +$134,844,672 | $21.99 | 72 |
| 2023 Q2 | 61,447,059 | $1,522,893,399 | +$1,522,893,346 | $23.80 | 56 |